The 150 most important questions in cancer research and clinical oncology series: questions 94-101  

作　　者：Cancer Communications 

机构地区：[1]Sun Yat-sen University Cancer Center,Guangzhou 510060,P.R.China

出　　处：《Cancer Communications》2018年第1期736-744,共9页癌症通讯（英文）

摘　　要：Since the beginning of 2017,Cancer Communications(former title:Chinese Journal of Cancer)has published a series of important questions regarding cancer research and clinical oncology,to provide an enhanced stimulus for can-cer research,and to accelerate collaborations between institutions and investigators.In this edition,the following 8 valuable questions are presented.Question 94.The origin of tumors:time for a new paradigm?Question 95.How can we accelerate the identification of biomarkers for the early detection of pancreatic ductal adenocarcinoma?Question 96.Can we improve the treatment outcomes of metastatic pancreatic ductal adenocarcinoma through precision medicine guided by a combination of the genetic and proteomic information of the tumor?Question 97.What are the parameters that determine a competent immune system that gives a complete response to cancers after immune induction?Question 98.Is high local concentration of metformin essential for its anti-cancer activity?Question 99.How can we monitor the emergence of cancer cells anywhere in the body through plasma testing?Question 100.Can phytochemicals be more specific and efficient at targeting P-glycoproteins to overcome multi-drug resistance in cancer cells?Question 101.Is cell migration a selectable trait in the natural evolution of carcinoma?

关 键 词：Tumor origin Polyploid giant cancer cell Pancreatic ductal adenocarcinoma Biomarker Liquid biopsy Spontaneous animal model Metastasis Chemotherapy Immunotherapy Precision treatment Vaccine immunization Metformin Circulating tumor cell Circulating tumor DNA CpG methylation Methylation haplotype block PHYTOCHEMICALS P-GLYCOPROTEIN Multi-drug resistance P-Glycoprotein inhibitor Epithelial-to-mesenchymal transition Migration Pro-migratory gene 

分 类 号：R73[医药卫生—肿瘤]